Moss B
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, MD 20892.
Curr Opin Biotechnol. 1992 Oct;3(5):518-22. doi: 10.1016/0958-1669(92)90080-3.
Over the past year improvements have been made in recombinant vaccinia virus gene expression and a new method for inserting DNA into the poxvirus genome has been developed, along with alternative methods for selecting recombinant viruses. Attenuated and non-replicating vaccinia virus and avian poxvirus vectors are now being used successfully. Field trials of an oral, wild-life rabies vaccine and phase 1 testing of human vaccines derived from vaccinia virus are underway.
在过去一年里，重组痘苗病毒基因表达取得了进展，开发出了一种将DNA插入痘病毒基因组的新方法，以及用于筛选重组病毒的替代方法。减毒和非复制性痘苗病毒及禽痘病毒载体目前正在成功应用。一种口服野生动物狂犬病疫苗的现场试验以及源自痘苗病毒的人类疫苗的1期试验正在进行中。
